...
首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo.
【24h】

Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo.

机译:血小板内皮细胞粘附分子(PECAM)在体内和离体的受损但未剥脱的内皮细胞上的血小板粘附/聚集中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND PURPOSE: We previously demonstrated that a monoclonal antibody (MoAb) with anti-CD31, anti-platelet-endothelial cell adhesion molecule (PECAM)-like properties delayed platelet adhesion/aggregation at a site of minor endothelial injury. To our knowledge, this was the first in vivo demonstration of an effect of anti-CD31. There was no exposure of collagen or basal lamina at the injured site, and the modulation of adhesion/aggregation at such sites has not received much study. The present investigation attempted to replicate the first with the use of a different MoAb, definitely characterized as anti-PECAM. In addition, an ex vivo investigation was performed to see whether the in vivo action of anti-PECAM could have been caused by an effect of the MoAb on the platelets rather than on the endothelium. METHODS: A helium-neon laser, in the presence of intravascular Evans blue, was used to injure the endothelium of arterioles on the surface of the mouse brain. Intravital microscopy was used to determine the number of seconds required for the light to initiate the first recognizable platelet aggregate forming at the injured site. Mice injected with vehicle were compared with mice injected with 2 mg/kg anti-PECAM through the tail vein. The injection was 10 minutes before challenge with the laser. Additional studies were performed of aggregation produced in vitro by arachidonate and by ADP added to platelet-rich plasma (PRP) prepared from blood taken from MoAb-treated and vehicle-treated mice. RESULTS: Aggregation latency was significantly prolonged (P<.02) by anti-PECAM (121+/-59 versus 65+/-26 seconds in controls; n=10 each). Aggregation ex vivo was not affected. CONCLUSIONS: PECAM is an important modulator of platelet adhesion/aggregation at sites of minor endothelial damage in brain arterioles. The data are consistent with the hypothesis that PECAM sites on the endothelium are involved and may be exposed by the injury to promote adhesion/aggregation. Since the endothelial cell layer is intact at these sites, mechanisms such as this offer important alternatives to the more commonly studied pathways of platelet activation, which require exposure of collagen and are not applicable in this model.
机译:背景与目的:我们先前证明具有抗CD31,抗血小板内皮细胞粘附分子(PECAM)样特性的单克隆抗体(MoAb)会在轻微的内皮损伤部位延迟血小板粘附/聚集。据我们所知,这是抗CD31作用的第一个体内证明。在受伤部位没有胶原蛋白或基底层的暴露,并且在这些部位的粘附/聚集的调节还没有得到太多研究。本研究试图使用不同的MoAb(肯定是抗PECAM)来复制第一个。另外,进行了离体研究以观察抗PECAM的体内作用是否可能是由于MoAb对血小板而不是对内皮的作用引起的。方法:使用氦氖激光在血管内埃文斯蓝的存在下,损伤小鼠脑表面的小动脉内皮。活体显微镜用于确定光引发在受伤部位形成的第一个可识别的血小板聚集体所需的秒数。将注射媒介物的小鼠与通过尾静脉注射2 mg / kg抗-PECAM的小鼠进行比较。注射是在用激光激发之前10分钟。对花生四烯酸酯体外产生的聚集以及通过将ADP添加到富含血小板的血浆(PRP)中进行了进一步的研究,所述富血小板血浆是从用MoAb治疗和载体治疗的小鼠抽取的血液中制备的。结果:抗PECAM显着延长了聚集潜伏期(P <.02)(对照组为121 +/- 59秒,而对照组为65 +/- 26秒;每组n = 10)。离体聚集不受影响。结论:PECAM是重要的调节剂,在脑小动脉内皮损伤程度小的地方血小板粘附/聚集。数据与以下假设相一致:内皮上的PECAM位点参与其中,并且可能因损伤而暴露出来,从而促进粘附/聚集。由于内皮细胞层在这些部位是完整的,因此这种机制为更常研究的血小板活化途径提供了重要的替代方法,后者需要暴露胶原蛋白,因此不适用于该模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号